Researchers have found that combining two cancer drugs with complementary mechanisms hits non-small cell lung cancer (NSCLC) harder than either alone — by both damaging tumor DNA and blocking the cancer’s ability to repair it.
The combination pairs HER3-DXd (patritumab deruxtecan) — an antibody-drug conjugate that acts like a guided “smart bomb,” delivering a DNA-damaging payload to cancer cells — with olaparib, a PARP inhibitor that blocks a key DNA-repair pathway. In lab models, the pairing increased DNA damage, triggered cancer-cell death, and slowed tumor growth. The study was published in Cell Reports Medicine.
A bonus immune effect
The combination also switched on the cGAS-STING innate immune pathway, boosting natural killer (NK) cell–mediated tumor killing. Notably, it worked across multiple genetically distinct forms of lung cancer and “was not dependent on any specific mutation,” said lead researcher Dr. Heidi Haikala of Tampere University, whose team included collaborators from Helsinki, Harvard Medical School and Dana-Farber.
Why it matters — and the caveats
A mutation-agnostic combination could, in principle, help a broad range of lung-cancer patients. But this is preclinical work in tumor organoids and mice: only a limited number of organoid lines were tested, the immune findings may not generalize, and potential toxicities — including liver effects — need careful evaluation before any human trials.